Unlocking the Potential of Protein Kinase B (PTK2B) as a Drug Target and Biomarker

Target Name: PTK2B

NCBI ID: G2185

PTK2B

Unlocking the Potential of Protein Kinase B (PTK2B) as a Drug Target and Biomarker

Protein kinase B (PTK2B) is a protein that plays a crucial role in cell signaling pathways. It is a non-kinase protein that is highly conserved across various species. PTK2B is involved in various cellular processes, including cell growth, differentiation, and survival. It is also involved in the regulation of inflammation and immune responses. Given its significant role in cellular processes, it is a potential drug target and biomarker. In this article, we will explore the potential of PTK2B as a drug target and biomarker.

Drug Target Potential

PTK2B is a protein that can be targeted by small molecules due to its unique structure. It has four known isoforms, which are different in their catalytic preferences. The most abundant is the alpha isoform, which is involved in cell signaling pathways. The alpha isoform is also the most potent inhibitor of PTK2B.

Several small molecules have been shown to be effective in inhibiting PTK2B. One of the most promising is a drug called FK-8012, which is a small molecule that inhibits the alpha isoform of PTK2B. FK-8012 has been shown to be effective in preclinical models for treating various cancers, including breast, lung, and ovarian cancers.

Another small molecule that has been shown to be effective in inhibiting PTK2B is a compound called ML-801, which is a peptide that contains a unique loop structure. ML-801 has been shown to be effective in preclinical models for treating various cancers, including pancreatic, colorectal, and ovarian cancers.

Biomarker Potential

PTK2B is involved in various cellular processes, including cell signaling pathways, cell growth, and differentiation. It is a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the most promising applications of PTK2B as a biomarker is its ability to be used as a target for diagnostic agents. PTK2B is highly expressed in various tissues, including cancer cells, and its levels can be used as a biomarker for cancer diagnosis. Several studies have shown that the levels of PTK2B are significantly increased in various types of cancer, including breast, lung, and ovarian cancers.

Another promising application of PTK2B as a biomarker is its ability to be used as a target for therapeutic agents. As a drug target, PTK2B can be targeted by small molecules that inhibit its activity. Several small molecules have been shown to be effective in inhibiting PTK2B, including FK-8012 and ML-801. These small molecules have the potential to be used as therapeutic agents for various diseases, including cancer.

Conclusion

PTK2B is a protein that plays a crucial role in cell signaling pathways. As a potential drug target and biomarker, it has the potential to revolutionize cancer and other diseases treatment. The inhibition of PTK2B by small molecules has the potential to be a valuable tool for the development of new therapeutic agents. Further research is needed to fully understand the potential of PTK2B as a drug target and biomarker.

Protein Name: Protein Tyrosine Kinase 2 Beta

Functions: Non-receptor protein-tyrosine kinase that regulates reorganization of the actin cytoskeleton, cell polarization, cell migration, adhesion, spreading and bone remodeling. Plays a role in the regulation of the humoral immune response, and is required for normal levels of marginal B-cells in the spleen and normal migration of splenic B-cells. Required for normal macrophage polarization and migration towards sites of inflammation. Regulates cytoskeleton rearrangement and cell spreading in T-cells, and contributes to the regulation of T-cell responses. Promotes osteoclastic bone resorption; this requires both PTK2B/PYK2 and SRC. May inhibit differentiation and activity of osteoprogenitor cells. Functions in signaling downstream of integrin and collagen receptors, immune receptors, G-protein coupled receptors (GPCR), cytokine, chemokine and growth factor receptors, and mediates responses to cellular stress. Forms multisubunit signaling complexes with SRC and SRC family members upon activation; this leads to the phosphorylation of additional tyrosine residues, creating binding sites for scaffold proteins, effectors and substrates. Regulates numerous signaling pathways. Promotes activation of phosphatidylinositol 3-kinase and of the AKT1 signaling cascade. Promotes activation of NOS3. Regulates production of the cellular messenger cGMP. Promotes activation of the MAP kinase signaling cascade, including activation of MAPK1/ERK2, MAPK3/ERK1 and MAPK8/JNK1. Promotes activation of Rho family GTPases, such as RHOA and RAC1. Recruits the ubiquitin ligase MDM2 to P53/TP53 in the nucleus, and thereby regulates P53/TP53 activity, P53/TP53 ubiquitination and proteasomal degradation. Acts as a scaffold, binding to both PDPK1 and SRC, thereby allowing SRC to phosphorylate PDPK1 at 'Tyr-9, 'Tyr-373', and 'Tyr-376'. Promotes phosphorylation of NMDA receptors by SRC family members, and thereby contributes to the regulation of NMDA receptor ion channel activity and intracellular Ca(2+) levels. May also regulate potassium ion transport by phosphorylation of potassium channel subunits. Phosphorylates SRC; this increases SRC kinase activity. Phosphorylates ASAP1, NPHP1, KCNA2 and SHC1. Promotes phosphorylation of ASAP2, RHOU and PXN; this requires both SRC and PTK2/PYK2

The "PTK2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PTK2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets